

Mutagenesis and Protoplast Fusion for Enhanced Bacteriocins Production

Wael Ahmed Bazaraa^{1*}, Abd-El-Nasser Abd El-Hafez Khattab², Eman Mohammed Ibrahim³

1-Food Science Department, Faculty of Agriculture, Cairo University, Giza, 12613, Egypt.

2-Genetics and Cytology Department, Genetic Engineering and Biotechnology Division, National Research Centre, Giza, 12622, Egypt.

3-The National Food Safety Authority, Cairo 11562, Egypt.

Abstract

Background and Objective: Induced mutagenesis is widely used to produce novel mutants with improved productivities. Ethyl methane-sulfonate-induced mutagenesis followed by intergeneric protoplast fusion were used to develop lactic acid bacterial strains with high antimicrobial activities.

Material and Methods: The antagonistic activities of seven LAB strains were assessed against seven indicator microorganisms using well diffusion assay. The highest two producers were subjected to ethyl methane-sulfonate mutagenesis followed by intergeneric protoplast fusion. Selection of the mutants and the fusants from the suggested fusion cross was based on the responses to different antibiotics.

Results and Conclusion: *Lactococcus lactis* subsp. *lactis* and *Bifidobacterium longum* showed the highest antimicrobial activities against most of the indicator microorganisms. Such activities were achieved at pH 2.0 and dramatically decreased by increasing the pH level. Ethyl methane-sulfonate-induced mutagenesis resulted in thirty mutants, four of which exhibited higher activities than their wild type parental strains (two for each parent). In an attempt to increase such activity, intergeneric protoplast fusions between LM 13 (resulting from *Lactococcus lactis* subsp. *lactis*) and BM 4 (resulting from *Bifidobacterium longum*) mutants were carried out. Twelve fusants were obtained. Interestingly, one fusant (F1) showed an increase in antimicrobial activity, compared to its parental strains. An increased range of 58.1 to 345.7% compared to the parental strain *Lactococcus lactis* subsp. *lactis* and a range of 51.5 to 168.5% for the second parental strain were noticed. The LM 13, LM 6, BM 4 and BM 12 mutants and the F1 fusant can be used in the preservation of food products.

Conflict of interest: The authors declare no conflict of interest.

How to cite this article

Bazaraa WA, Khattab AA, Ibrahim EM. Mutagenesis and Protoplast Fusion for Enhanced Bacteriocins Production. *Appl Food Biotechnol* 2021; 8(2):133-142. <http://dx.doi.org/10.22037/afb.v8i2.32505>

Article Information

Article history:

Received 9 Oct, 2020
Revised 2 Dec 2020
Accepted 12 Jan 2021

Keywords:

- Bacteriocins
- *Bifidobacterium longum*
- Ethyl methane sulfonate
- Intergeneric protoplast fusion
- *Lactococcus lactis* subsp. *lactis*

*Corresponding authors:

Wael Ahmed Bazaraa,
Food Science Department,
Faculty of Agriculture, Cairo
University, Giza, 12613,
Egypt.

Tel: 00201004154949

E-mail:

waelbazaraa@hotmail.com

1. Introduction

Lactic acid bacteria (LAB) play important roles in various fermented foods, including dairy, meat and vegetable products. LAB strains are able to secrete many inhibitory compounds such as organic acids (lactic and acetic), ethanol, diacetyl, H₂O₂ [1] and bacteriocins [2]. Bacteriocins are small peptides that are stable in a wide range of pH and temperatures. They are common examples of natural antimicrobial agents that can be used in food systems to extend product microbial - shelf life [3], and are generally considered as safe (GRAS) by the United States Food and Drug Administration (US FDA) [4]. Bacteriocins are generally divided into Class I (post-translationally modified peptides, lantibiotics with less than 28 amino

acids small membrane-active peptides (<5 kDa), linear or globular peptides), Class II (unmodified peptides, non-lanthionine, 30-60 amino acids (<10 kDa), always exhibit unique properties of heat tolerance, and positive charges), and Class III (large proteins (>30 kDa), heat unstable). For example, Class I bacteriocins operon, like nisin, includes a structural gene, genes that give accessory proteins responsible for cell modifications (e.g. proteolysis, command peptide processing, dehydration, cyclization), transport genes (that encode the ABC superfamily transport proteins for transmission peptides), regulatory genes, and immunity genes that confer resistance to the producer strains [5]. Bacteriocins can kill or inhibit many food-borne path-

ogenic and spoilage bacteria such as: *Salmonella typhimurium*, *Listeria monocytogenes*, *Staphylococcus* spp., *Escherichia coli*, *Yersinia* spp. [6-8] as well as spore-forming bacteria of *Bacillus* and *Clostridium* genera [9]. Bacteriocins-producing LAB strains have been used as probiotics and bio-preservatives in food stuffs such as meat products [10,11], dairy products [12,13], fresh fish, seafoods [14,15], salads and vegetables [6,16] and as natural preservatives in food packaging [17,18].

In nature, mutations occur randomly at extremely low rates (one mutant cell per 10^6 to 10^7 cells per generation). Mutations can result in changes in the nucleotide sequences of DNA (e.g. point mutation, double mutation, deletion and insertion) due to the expose to different mutagenic agents. Induced mutagenesis is widely used for producing novel mutant strains with improved phenotypes. The most common used mutagenic chemicals include: ethyl methane-sulfonate (EMS), methyl methane-sulfonate, nitrous acid and nitrosoguanidine (NTG) [19]. The most mainstream mutagen utilized to improve bacterial strains is EMS, which ordinarily produces assortments of point changes in the bacterial DNA. Via these point changes, extraordinary mutants are created at increased levels in correlation with the regular changes to upgrade the bacteriocin production [20,21]. Furthermore, ultraviolet (UV) and gamma irradiation are used as physical mutagenic agents [22]. They have already been used to improve the technological and physical characteristics of LAB. To increase lactic acid (LA) production, various mutagenic chemicals have been used such as: nitrous acid for *Lactobacillus delbrueckii* [23] and EMS for *L. pentosus* [24]. However, UV irradiation has increased the LA production and antimicrobial activity of *L. fermentum* against *Escherichia coli* [25]. Moreover, heavy ion irradiation was successfully used to increase LA production of *L. thermophilus* [26], while gamma irradiation was utilized by Abdallah et al. [27] to increase the antimicrobial activity of *L. acidophilus* and *Streptococcus thermophilus* against the antibiotic resistant *Salmonella* sp.

An important target of biotechnological studies includes the engineering of improved microbial cells for the synthesis of industrially valuable metabolites [28]. To achieve this target, different methods such as protoplast fusion and genetic engineering are usually employed. Protoplast fusion is an easy and cost effective technique that allows the exchange of entire genomes, through genetic recombination process between related or unrelated genera of microorganisms [19]. Protoplasts can be isolated from bacterial cells by digesting the cell walls with lysozyme in the presence of osmotic stabilizers. The fusion of protoplasts occurs by chemical phosgens such as polyethylene glycol (PEG). This technique has great potentials in improving industrial strains through the transfer of genes between the parental strains in a random and non-

specialized way, reversing the transfer by genetic engineering. The protoplast fusion technique can be utilized by developing a robust plan to isolate and develop fusant strains with specific and important productive characteristics [20]. It has been used to increase LA production of *L. rhamnosus* by 3.1 [29] and 1.8-folds [30] and *L. fermentum* strains by 4-folds [31] using intraspecific fusion. The intergeneric fusion between *L. delbrueckii* and *Acetobacter pasteurianus* increased the yield of LA production by 5-folds [32]. Antifungal activity of *L. plantarum* has been improved by 3 rounds of protoplast fusion with *L. helveticus* [33]. The antifungal activities of the resulting fusants (F3C2 and F3A3) reached 1.92 and 2.00-fold, respectively, compared to parental strains. Intergeneric protoplast fusion has rarely been used to improve production of bacteriocins by LAB. So, this study was carried out to investigate antimicrobial activities of various LAB and improve these activities using chemical mutagenesis with EMS followed by protoplast fusion.

2. Materials and Methods

2.1. Materials

MRS broth, Brain Heart Infusion (BHI) broth, Plate Count Agar (PCA), different antibiotic disks and anaerobic jars were purchased from Oxoid (UK). Skim milk (SM) was obtained from the Dairy Science Department, Faculty of Agriculture, Cairo University, Giza, Egypt. Egg white lysozyme, mutanolysin enzymes, PEG 6000, EMS and 2[4-(2-hydroxyethyl)-1-piperazinyl] ethanesulfonic acid (HEPES) were purchased from Sigma- Aldrich (St. Louis, MO, USA).

2.2. Methods

2.2.1. Cultivation of lactic acid bacteria

The LAB strains (Table 1) were separately cultured in MRS broth for 48 h at 37 °C in anaerobic conditions and stored at 4 °C until use. Strains were monthly recovered from the refrigerated stock for 3 consecutive days at 37 °C in bottles containing 100 ml of sterile SM (121°C, 15 min). Indicator bacteria (Table 2) were separately cultivated in BHI broth at 37 °C for 24 h and recovered monthly.

2.2.2. Antimicrobial activity assay

The antimicrobial activity assessment was carried out using well diffusion assay as described by Bazaraa et al. [15]. Briefly, 0.1 ml of each indicator microorganism (24 h old) containing 1.0×10^7 CFU ml⁻¹ was spread plated over the surface of PCA medium and three wells (5 mm in diameter) were made using the top of sterile Pasteur pipette. Wells were filled with 50 µl of each two-days cultivated LAB strain in SM. Plates were incubated at 37 °C for 48 h and the inhibition zones around the wells were measured in mm.

Table 1. The lactic acid bacteria and their sources

Strain	Code	Source
<i>Lactococcus lactis</i> subsp. <i>lactis</i>	1821	
<i>Lactobacillus rhamnosus</i>	1937	
<i>Lactobacillus casei</i>	441	NRRL, Northern Regional Research Laboratories, Peoria, IL, USA
<i>Pediococcus acidilactici</i>	14858	
<i>Bifidobacterium bifidum</i>	41410	
<i>Bifidobacterium longum</i>	15708	ATCC, American Type Culture Collection, Rockville, Maryland, USA
<i>Streptococcus thermophilus</i>	-	STS, Chr. Hansen, S lab, Denmark

Table 2. The indicator microorganisms and their sources

Strain	Code	Source
<i>Bacillus cereus</i>	33018	
<i>Escherichia coli</i>	35218	
<i>Salmonella typhimurium</i>	14028	ATCC, American Type Culture Collection, Rockville, Maryland, USA
<i>Staphylococcus aureus</i>	25923	
<i>Listeria monocytogenes</i>	7644	
<i>Bacillus subtilis</i>	765	NRRL, Northern Regional Research Laboratories, Peoria, IL, USA
<i>Klebsiella pneumoniae</i>	49	FS, Food Science Department, Faculty of Agriculture, Cairo University, Giza, Egypt.

2.2.3. Effect of pH on the antimicrobial activity

Active 24 h old LAB strains were separately grown in SM for 48 h at 37 °C. The pH of each culture was then adjusted to different pH levels (2.0, 4.0 and 6.0) using either 1 N HCL or NaOH and the antimicrobial activity was assessed as previously described.

2.2.4. Ethyl methane-sulfonate mutagenesis

Five ml of 24 h old LAB strains separately cultivated in MRS were centrifuged (5,600 x g, 4 °C, 3 min). Cells were resuspended in 5 ml of sodium phosphate buffer (pH 7.0, 50 mM) and then EMS was added to the suspension to achieve a final concentration of 200 mM. Tubes were agitated (100 rpm) at 30 °C for 20, 40 and 60 min. Then, a 500 µl of sodium thiosulphate (0.4 M) was added to tubes to neutralize the EMS. Cells were harvested by centrifugation at (5,600 x g, 10 min) at 4 °C and washed twice with the same buffer. The cell pellets were resuspended in phosphate buffer (pH 7.0, 50 mM), and appropriate dilutions (10⁻¹ to 10⁻³) were plated on the surface of MRS plates. Then, various antibiotic disks were placed on the surface of these plates and incubated at 37 °C for three days [20,21].

2.2.5. Selection of mutants

Initial antibiotic sensitivity tests [34] were carried out on wild type strains using discs containing the following

antibiotics with specific concentrations (µg/disc): amoxicillin, 25; chloramphenicol, 10; colistin, 25; doxycycline, 30; gentamycin, 10; polymyxin B, 300; rifampicin, 5; streptomycin, 10; sulphamethoxazole, 500 and tobramycin, 10. The most effective antibiotic disc was used for the selection of resistant mutants. Antibiotic-resistant mutants were collected from the nearest area around the discs (inhibition zones) and transferred to MRS plates for further studies.

2.2.6. Protoplast fusion

2.2.6.1. Protoplast formation buffer

The protoplast formation buffer (PB) [35] contained: MgCl₂, 1 mM; raffinose, 300 mM; gelatin, 0.5% and HEPES (pH 7.0, 20 mM).

2.2.6.2. Lactic acid bacteria carrying medium

The Lactic acid bacteria carrying medium (LCM) described by Efthymiou and Hansen [36] was utilized and contained (g l⁻¹): glucose, 20; trypticase peptone, 10; yeast extract, 5; tryptose, 3; K₂HPO₄, 3; KH₂PO₄, 3; tri-ammonium citrate, 2; sodium acetate, 1; Tween-80, 1 and L-cysteine-HCL H₂O, 0.2. The pH was adjusted to 6.8. For each liter of this medium, 5 ml of salt solution contains: (g/100 ml): MgSO₄.7H₂O, 11.50; FeSO₄.7H₂O, 1.68 and MnSO₄. 2H₂O, 2.40 were added.

2.2.6.3. Protoplast regeneration medium

The protoplast regeneration medium (PRM) was similar to LCM without the addition of Tween 80, and supplemented with the following ingredients: 1% glucose; 0.5% bovine serum albumin (BSA) (2.5%, w v⁻¹); 2.5% gelatin; 2.5% MgCl₂; 25 mM CaCl₂; 300 mM raffinose and 2% agar [35]. The PRM was prepared as follow: raffinose and gelatin were dissolved in a portion of LCM (without Tween-80) with constant heating (50 °C in water bath) and stirring. Then, 2% agar was added to this solution and sterilized at 121 °C for 15 min. Glucose, BSA, and salts were dissolved in the rest of LCM (without Tween-80), sterilized by filtration (0.45 µ Millipore filter) and directly added to the medium before pouring at 50 °C.

2.2.6.4. Selection of the proposed cross

To perform protoplast fusion, antibiotic sensitivity test [34] was first carried out on parental strains, as negative controls, using different discs with specific antibiotic concentrations (µg/disc): ampicillin, 10; chloramphenicol, 30; erythromycin, 15; kanamycin, 30; lincomycin, 2; rifampicin, 30; streptomycin, 10 and tobramycin, 30. Based on the results, the adequate protoplast crossing was selected.

2.2.6.5. Protoplast fusion technique

Protoplast fusion was carried out according to Chassy [37]. Ten ml of MRS broth were inoculated with each parental strain and incubated overnight at 37 °C. Then, 1.5 ml of the culture were sub-cultured into 50 ml of LCM medium containing: 0.1% glucose; 1% glycine and 20 mM threonine, and grown for 4 h at 37 °C. Cells were then harvested, washed with PB and resuspended in 2 ml of the same buffer containing 400,000 U of lysozyme and 50 U of mutanolysin. Cells were incubated at 37 °C with gentle agitation (100 rpm). Protoplast formation was microscopically verified using phase-contrast microscope. Cell wall

removal and protoplast formation were observed within 1 h of incubation. Protoplasts were harvested by centrifugation at 4,000 x g for 10 min at 4 °C and resuspended in PB. Two protoplast suspensions from different parental strains were mixed at 1:1 ratio, and then harvested by centrifugation at 4,000 x g for 10 min at 4 °C. Supernatants were discarded and pellets were suspended in 1 ml of PB containing 100 µl of 40% PEG 6000 for 6 min. Suspension was centrifuged and pellet was resuspended in 3 ml of PB. Then, 5 ml of soft PRM (0.4% agar) medium at 45 °C was mixed with 0.5 ml of protoplast suspension, plated immediately onto the surface of solid PRM agar plates and incubated at 37 °C. After transferring the selected antibiotic discs, plates were incubated at 37 °C for three days. Resistant fusants were collected, sub-cultured, tested for antimicrobial activity and stored at 4 °C.

2.2.7. Statistical analysis

Statistical comparisons were carried out using one way Analysis of Variance utilizing the Costate software [38] and expressed as mean±standard deviation. All experiments were performed in triplicate.

3. Results and Discussion

3.1. Antimicrobial activity of lactic acid bacteria

The antagonistic activities of the tested LAB strains cultured in SM (initial pH of 2.0) for 48 h against selected indicator microorganisms are shown in Table 3 as diameter (mm) of clear zones. Results indicated that all used indicator microorganisms were variously inhibited by the bacteriocins produced by all the tested LAB. Data (Table 3) revealed that the highest antimicrobial activities belonged to bacteriocins from *Bifidobacterium (B.) longum* and *L. lactis* subsp. *lactis*, where the inhibition zones for each were the highest in 71.4% of the indicator microorganisms.

Table 3. Antagonistic activities of lactic acid bacteria

LAB*	Indicator microorganisms						
	<i>Staphylococcus aureus</i>	<i>Salmonella typhimurium</i>	<i>Bacillus cereus</i>	<i>Bacillus subtilis</i>	<i>Escherichia coli</i>	<i>Klebsiella pneumonia</i>	<i>Listeria monocytogenes</i>
	Inhibition zone (mm) ± SD						
<i>Bifidobacterium longum</i>	**10.3 ^a ± 0.00	8.3 ^b ± 0.00	8.3 ^a ± 0.00	7.6 ^a ± 0.00	7.3 ^b ± 0.00	5.4 ^a ± 0.00	6.6 ^d ± 0.00
<i>Streptococcus thermophilus</i>	9.6 ^b ± 0.41	6.6 ^b ± 0.02	6.6 ^d ± 0.06	7.6 ^a ± 0.01	11.3 ^a ± 0.03	5.6 ^e ± 0.00	7.6 ^c ± 0.01
<i>Lactococcus Lactis</i>	5.5 ^c ± 0.00	8.6 ^a ± 0.00	7.8 ^a ± 0.00	3.5 ^b ± 0.00	11.0 ^a ± 0.00	5.3 ^d ± 0.14	10.5 ^a ± 0.00
<i>Lactobacillus casei</i>	4.3 ^d ± 0.01	5.2 ^c ± 0.02	3.3 ^c ± 0.03	3.1 ^{cd} ±0.00	4.5 ^c ± 0.05	4.5 ^b ± 0.03	5.2 ^e ± 0.04
<i>Pediococcus acidilactici</i>	3.6 ^d ± 0.02	5.0 ^b ± 0.02	5.2 ^c ± 0.01	3.2 ^c ± 0.01	6.6 ^a ± 0.03	3.5 ^d ± 0.03	4.2 ^f ± 0.01
<i>Lactobacillus rhamnosus</i>	3.5 ^e ± 0.00	5.3 ^b ± 0.00	4.0 ^d ± 0.01	3.3 ^c ± 0.01	4.9 ^{de} ±0.00	4.6 ^{bc} ± 0.01	9.1 ^b ± 0.19
<i>Bifidobacterium bifidum</i>	3.4 ^e ± 0.01	4.0 ^d ± 0.03	3.4 ^e ± 0.01	3.0 ^d ± 0.00	5.4 ^d ± 0.01	4.3 ^b ± 0.00	5.4 ^e ± 0.03

*LAB strains were allowed to grow at 37 °C for 48 h in SM. The pH of the culture was then adjusted to 2.0.

**Means followed by different superscripts (within columns) and different subscripts (within rows) are significantly different ($p < 0.05$).

In antagonistic activity, *Streptococcus thermophilus* followed *B. longum* and *L. lactis* subsp. *lactis*, where it showed the highest activity against 42.9% of the indicator microorganisms. On the other hand, *B. bifidum* was the least in its antimicrobial activities. *Staphylococcus aureus* was most sensitive (10.3 mm) against bacteriocins from *B. longum* while *Salmonella typhimurium* and *Bacillus cereus* were most sensitive to bacteriocins of *B. longum* and *L. lactis* subsp. *lactis* with no significant differences ($p < 0.05$) between them. Bacteriocins of *B. longum* and *Streptococcus thermophilus* equally ($p < 0.05$) inhibited (7.6 mm each) *Bacillus subtilis*. Similarly, *Streptococcus thermophilus* and *L. lactis* subsp. *lactis* showed the same effect (11.3 and 11.0 mm) with no significant differences on *E. coli*. Bacteriocins of *B. longum*, *Streptococcus thermophilus* and *L. lactis* subsp. *lactis* equally inhibited (5.4, 5.6 and 5.3 mm, respectively) *Klebsiella pneumoniae*. Finally, *Listeria monocytogenes* was mostly inhibited by bacteriocins of *L. lactis* subsp. *lactis*. Bazarra et al. [15] reported similar results where *L. lactis* subsp. *lactis* was the most effective tested LAB in inhibiting selected food pathogenic and spoilage microorganisms. Antimicrobial activities obtained from LAB were seen against Gram-positive and Gram-negative bacteria (Table 3). Similar results were reported by Nomoto [39]. However, it is well known that nisin is generally active against Gram-positive bacteria while it is inactive against Gram-negative bacteria. This is linked to the resistance of the outer membranes of the Gram-negative bacteria which prevents this bacteriocin from entering the cells [40]. Such obtained activities against the Gram-negative indicator bacteria could be due to the synthesis of organic acids, diacetyl, hydrogen peroxide and possibly other bacteriocins [41]. Since *B. longum* and *L. lactis* subsp. *lactis* showed the highest

antimicrobial activities against the selected indicator microorganisms, they were selected for further experiments.

3.2. Effect of pH on the antimicrobial activities

Antimicrobial activities of *B. longum* and *L. lactis* subsp. *lactis* at different pH levels (2.0, 4.0 and 6.0) are shown in Table 4. Bacteriocins produced by the selected LAB showed the highest activities at pH 2.0 followed by significant ($p < 0.05$) decreases at pH 4.0 and 6.0. At pH 8.0, the antimicrobial activities were completely lost (data not shown). Similar results were recorded by Rabie et al. [42] and Bazarra et al. [15]. Joshi et al. [43] reported that the maximum bacteriocin activities were achieved at pH values below 5.0. Similarly, pH range of 2.0-3.0 was necessary to reach the highest bacteriocin activities followed by a dramatic decrease at higher pH values [44]. Adesina and Enerjiöfi [45] reported the highest bacteriocin activities at the acidic pH range of 2.0 to 5.0. Therefore, the use of bacteriocins in acidic and acidified foods is recommended to extend food shelf life.

3.3. Mutagenesis

The resistance of *L. lactis* subsp. *lactis* and *B. longum* against preloaded various antibiotic discs was evaluated. Results revealed high sensitivity of *L. lactis* subsp. *lactis* against 300 µg rifampicin (27 mm) followed by chloramphenicol (20 mm) and doxycycline (20 mm), while the strain was resistant against other antibiotics (Table 5). In contrast, *B. longum* was only resistant against amoxicillin and sensitive to other antibiotics especially gentamycin (25 mm) followed by chloramphenicol (20 mm) and doxycycline (15 mm). Therefore, such antibiotics were used as markers to select the most resistant mutants.

Table 4. Antagonistic activity of lactic acid bacteria at various pH levels (2, 4 and 6)

Indicator microorganisms	<i>L. lactis</i> subsp. <i>lactis</i>			<i>Bifidobacterium longum</i>		
	2	4	6	2	4	6
<i>Staphylococcus aureus</i>	*5.5 ^d _c ±0.05	2.7 ^c _d ±0.05	2.3 ^c _d ±0.05	10.3 ^a _a ±0.05	7.0 ^a _b ±0.08	6.3 ^a _{bc} ±0.05
<i>Salmonella typhimurium</i>	8.6 ^b _a ±0.05	5.6 ^b _b ±0.05	5.0 ^b _b ±0.05	8.3 ^b _a ±0.05	5.0 ^b _b ±0.05	3.6 ^b _c ±0.05
<i>Bacillus cereus</i>	7.8 ^c _a ±0.05	6.6 ^{ab} _{bc} ±0.05	4.0 ^b _d ±0.08	8.3 ^b _a ±0.05	6.6 ^{ab} _{bc} ±0.05	6.0 ^a _c ±0.08
<i>Bacillus subtilis</i>	3.5 ^e _c ±0.05	3.0 ^c _c ±0.05	1.6 ^c _d ±0.08	7.6 ^c _a ±0.05	5.6 ^b _b ±0.05	3.6 ^b _c ±0.05
<i>Escherichia coli</i>	11.0 ^a _a ±0.05	7.6 ^a _b ±0.05	7.0 ^a _b ±0.08	7.3 ^d _b ±0.05	6.3 ^{ab} _{bc} ±0.05	5.3 ^a _c ±0.05
<i>Klebsiella pneumoniae</i>	5.3 ^d _a ±0.00	3.6 ^c _b ±0.05	2.3 ^c _c ±0.05	5.4 ^f _a ±0.05	4.0 ^c _b ±0.00	2.3 ^c _c ±0.05
<i>Listeria monocytogenes</i>	10.5 ^a _a ±0.05	6.0 ^b _b ±0.05	5.0 ^b _c ±0.05	6.6 ^e _b ±0.05	4.3 ^c _c ±0.05	3.3 ^{bc} _d ±0.05

*Means activity (mm) followed by different superscripts (within columns) and different subscripts (within rows) are significantly different ($p < 0.05$).

Table 5. Antibiotic susceptibility of the selected bacteriocins hyper-producing lactic acid bacteria

Strain	Antibiotic disc									
	*AMX +25	C 10	GEN 10	CT 25	RI 5	PB 300	S 10	SXT 500	DOX 30	TOB 10
<i>L. lactis</i> subsp. <i>lactis</i>	R	**20	R	R	27	R	R	R	20	R
<i>Bifidobacterium longum</i>	R	20	25	11	10	10	12	10	15	7

*AMX, amoxicillin; C, chloramphenicol; GEN, gentamycin; CT, colistin; RI, rifampicin; PB, polymyxin B; S, streptomycin; SXT, sulphamethoxazole; DOX, doxycycline; TOB, tobramycin. + Concentration (µg/disc). R= resisted (no clear zone).

**Means of diameter of inhibition zones (mm).

3.4. EMS mutagenesis

In general, 15 antibiotic resistant mutants were selected from each strain and their antimicrobial activities were assessed (Tables 6 and 7). Table 6 shows the antimicrobial activities of *L. lactis* subsp. *lactis* mutants against indicator microorganisms. All the 15 mutants (LM 1 to LM 15) demonstrated higher ($p<0.05$) activities against *Staphylococcus aureus* and *Bacillus subtilis* when compared to those the parental strains did. On the other hand, mutants showed varied results on the rest of indicator microorganisms. For example, only 26.7% of the mutants showed higher activities against *Listeria monocytogenes*, while 26.6, 86.7 and 86.7% of the mutants were of higher

activities against *E. coli*, *Salmonella typhimurium*, and *Bacillus cereus*, respectively. Mutant LM13 recorded the highest antimicrobial activities against all indicator microorganisms followed by LM6. The improvement range for LM 13 was from 39.5 (*Salmonella typhimurium*) to 317.1% (*Bacillus subtilis*). While it was from 9.1 (*E. coli*) to 271.4% (*Bacillus subtilis*) for the mutant LM 6. Table 7 represents antimicrobial activities of the *B. longum* mutants against indicator microorganisms. All mutants showed various responses; for example only 20.0 and 33.3% of the mutants were of higher antimicrobial effects against *Staphylococcus aureus* and *E. coli*, respectively compared to those of the parental strains.

Table 6. Antagonistic activity of *Lactobacillus lactis* subsp. *lactis* mutants

Mutants	Indicator microorganisms						
	<i>Staphylococcus aureus</i>	<i>Salmonella typhimurium</i>	<i>Bacillus cereus</i>	<i>Bacillus subtilis</i>	<i>Escherichia coli</i>	<i>Klebsiella pneumoniae</i>	<i>Listeria monocytogenes</i>
	Inhibition zone (mm ± SD)						
Parent	*5.5 ^h _d ± 0.05	8.6 ^c _b ± 0.00	7.8 ^f _c ± 0.05	3.5 ^g _e ± 0.00	11.0 ^e _a ± 0.05	5.3 ^e _d ± 0.00	10.5 ^d _a ± 0.00
LM1	7.3 ^{ef} _c ± 0.05	10.0 ^{cd} _b ± 0.00	10.6 ^e _b ± 0.05	11.3 ^{cde} _a ±0.05	10.0 ^f _b ± 0.00	7.0 ^c _c ± 0.00	10.6 ^d _b ± 0.05
LM2	8.0 ^{de} _c ±0.00	10.0 ^{cd} _{ab} ±0.00	10.6 ^e _a ± 0.05	10.6 ^{ef} _a ± 0.05	9.3 ^{bc} _{bc} ±0.05	9.0 ^b _{cd} ±0.00	9.6 ^{bc} _{±0.08}
LM3	7.5 ^{ef} _d ± 0.05	10.0 ^{cd} _{ab} ± 0.00	10.6 ^e _a ± 0.05	10.3 ^{ef} _a ± 0.05	7.6 ^h _d ± 0.05	9.0 ^b _c ± 0.00	9.3 ^c _{bc} ±0.05
LM4	7.0 ^f _e ± 0.00	10.6 ^{bc} _b ± 0.05	9.0 ^f _c ± 0.05	11.6 ^{cde} _a ±0.05	7.0 ⁱ _e ± 0.00	6.3 ^d _e ± 0.05	8.0 ^f _d ± 0.00
LM5	6.0 ^g _d ± 0.00	12.0 ^a _a ± 0.00	12.6 ^{cd} _{ab} ±0.00	11.0 ^{def} _b ±0.00	10.6 ^f _b ± 0.05	7.6 ^c _c ± 0.05	5.0 ^g _e ± 0.00
LM6	11.0 ^b _d ± 0.00	12.3 ^{abc} _{± 0.05}	13.3 ^{bc} _{ab} ±0.05	13.0 ^b _{ab} ±0.00	12.0 ^d _c ±0.00	9.0 ^b _e ± 0.00	10.6 ^d _d ±0.05
LM7	12.0 ^a _a ± 0.00	10.0 ^{cd} _c ± 0.00	12.6 ^{cd} _a ± 0.05	10.3 ^{ef} _{bc} ±0.07	11.0 ^e _b ± 0.00	9.0 ^b _d ± 0.00	10.6 ^d _{bc} ±0.05
LM8	9.0 ^d _{cd} ±0.00	8.6 ^e _d ± 0.05	10.6 ^e _b ± 0.05	12.0 ^{bcd} _a ±0.05	9.0 ^g _{cd} ± 0.00	7.0 ^c _e ± 0.00	9.6 ^e _c ± 0.05
LM9	10.0 ^c _e ± 0.00	11.6 ^{ab} _{bc} ±0.06	12.0 ^d _{ab} ±0.00	12.6 ^{bc} _a ± 0.05	11.0 ^e _{cd} ±0.00	10.0 ^a _e ± 0.00	10.6 ^d _{de} ±0.05
LM10	12.0 ^a _{ab} ±0.00	12.6 ^a _a ± 0.05	12.0 ^d _{ab} ±0.00	12.6 ^{bc} _a ± 0.05	4.0 ⁱ _c ± 0.00	3.0 ^g _d ± 0.00	11.6 ^c _b ± 0.05
LM11	10.0 ^c _b ± 0.00	2.6 ^f _d ± 0.05	10.6 ^e _b ± 0.05	13.0 ^b _a ± 0.05	3.0 ^k _d ±0.00	4.6 ^f _c ± 0.05	10.0 ^{de} _{bc} ±0.00
LM12	9.0 ^b _b ± 0.00	10.6 ^{bc} _a ± 0.05	9.0 ^f _b ± 0.00	10.0 ^f _a ± 0.00	10.0 ^f _a ±0.00	6.0 ^d _d ± 0.00	7.6 ^f _c ± 0.05
LM13	12.6 ^a _d ± 0.05	12.0 ^a _d ± 0.00	16.0 ^a _b ± 0.00	14.6 ^a _c ± 0.00	18.0 ^a _a ±0.00	10.6 ^a _e ± 0.05	14.6 ^a _c ± 0.05
LM14	10.0 ^c _d ± 0.00	10.6 ^{bc} _d ±0.05	14.0 ^b _b ±0.00	11.6 ^{cde} _c ±0.57	16.0 ^b _a ± 0.00	4.0 ^f _e ± 0.00	13.6 ^b _b ±0.05
LM15	12.6 ^a _c ± 0.05	10.0 ^{cd} _d ±0.00	13.0 ^{bcd} _b ±0.00	10.6 ^{ef} _d ± 0.05	14.0 ^c _a ± 0.05	9.0 ^b _e ± 0.00	13.0 ^b _b ±0.00

*Means followed by different superscripts (within columns) and different subscripts (within rows) are significantly different ($p<0.05$).

Table 7. Antagonistic activity of *Bifidobacterium longum* mutants

Mutants	Indicator microorganisms						
	<i>Staphylococcus aureus</i>	<i>Salmonella typhimurium</i>	<i>Bacillus cereus</i>	<i>Bacillus subtilis</i>	<i>Escherichia coli</i>	<i>Klebsiella pneumoniae</i>	<i>Listeria monocytogenes</i>
	Inhibition zone (mm ± SD)						
Parent	*10.3 ^d _a ±0.01	8.3 ^c _b ±0.01	8.3 ^g _b ±0.01	7.6 ^f _c ± 0.01	7.3 ^c _c ± 0.01	5.4 ^f _e ±0.01	6.6 ^f _d ±0.01
BM1	6.3 ^g _c ±0.05	10.6 ^d _a ±0.05	10.3 ^c _a ±0.09	10.6 ^d _a ± 0.05	10.6 ^c _a ±0.09	5.3 ^f _d ±0.05	7.3 ^f _b ±0.05
BM2	10.3 ^d _b ±0.05	10.3 ^d _b ±0.05	12.6 ^e _a ±0.05	10.6 ^d _b ± 0.05	10.3 ^c _b ±0.05	9.3 ^b _c ±0.05	10.3 ^c _b ±0.05
BM3	10.6 ^d _b ±0.05	10.3 ^b _b ±0.05	7.3 ^h _d ±0.05	10.6 ^d _b ± 0.09	6.3 ^f _e ±0.05	8.3 ^c _c ±0.05	11.3 ^a _a ±0.06
BM4	14.6 ^b _a ±0.05	16.3 ^a _a ±0.05	14.6 ^b _b ±0.05	13.6 ^a _c ± 0.08	16.3 ^a _a ±0.05	10.6 ^a _d ±0.08	15.3 ^a _b ±0.05
BM5	10.3 ^d _a ±0.05	8.3 ^c _d ±0.05	11.3 ^d _a ±0.05	10.3 ^b _b ± 0.05	8.3 ^d _d ±0.05	9.3 ^b _c ±0.05	8.3 ^c _d ±0.05
BM6	12.0 ^c _a ±0.05	11.3 ^c _b ±0.08	7.6 ^h _e ± 0.09	11.3 ^c _b ± 0.05	5.6 ^g _f ±0.09	10.6 ^a _c ±0.09	9.6 ^d _d ±0.08
BM7	9.3 ^e _a ±0.05	2.3 ^h _d ±0.05	2.3 ⁱ _d ± 0.05	4.3 ^h _b ± 0.05	2.3 ⁱ _d ±0.05	3.3 ^h _c ±0.05	3.3 ⁱ _c ± 0.05
BM8	7.3 ^f _a ±0.05	1.6 ⁱ _e ± 0.05	3.3 ^j _c ±0.05	4.3 ^h _b ± 0.05	2.3 ⁱ _d ±0.05	2.6 ^j _d ±0.09	4.3 ^h _b ± 0.05
BM9	7.6 ^a _a ±0.05	3.3 ^g _d ±0.05	5.6 ^b _b ±0.08	7.3 ^a _a ± 0.05	7.6 ^a _a ±0.09	5.6 ^{ef} _b ±0.05	4.6 ^c _c ± 0.08
BM10	5.3 ^h _b ±0.05	5.6 ^f _b ±0.08	4.6 ^c _c ±0.09	3.3 ⁱ _d ± 0.05	6.6 ^f _a ±0.05	4.6 ^g _c ±0.08	6.0 ^g _a ± 0.05
BM11	4.3 ⁱ _a ± 0.05	3.3 ^g _b ±0.05	2.3 ^j _c ±0.05	2.6 ^j _c ±0.05	3.3 ^h _b ±0.05	3.6 ^h _b ±0.05	3.6 ^h _b ±0.08
BM12	6.3 ^g _f ± 0.05	13.6 ^b _b ±0.08	15.3 ^d _a ±0.05	12.6 ^b _c ± 0.05	12.6 ^b _c ±0.05	9.3 ^b _c ±0.05	10.3 ^c _d ±0.05
BM13	4.3 ⁱ _f ± 0.05	13.3 ^b _b ±0.05	14.6 ^b _a ±0.05	13.0 ^a _b ± 0.05	5.3 ^g _e ±0.05	7.3 ^d _d ±0.05	9.3 ^d _c ±0.05
BM14	10.0 ^d _a ±0.05	2.3 ^h _f ± 0.05	9.3 ^b _b ±0.05	8.6 ^c _c ± 0.05	4.3 ^h _e ±0.05	8.3 ^c _c ± 0.05	5.3 ^h _d ±0.05
BM15	18.0 ^a _a ±0.16	2.3 ^h _d ± 0.05	10.0 ^c _b ±0.05	10.3 ^d _b ± 0.05	3.3 ⁱ _d ± 0.05	5.3 ^f _c ±0.05	6.0 ^g _c ±0.05

*Means followed by different superscripts (within columns) and different subscripts (within rows) are significantly different ($p<0.05$).

In contrast, 46.7% of the mutants showed antimicrobial activity improvements against and *Salmonella typhimurium*, *Bacillus cereus* and *Listeria monocytogenes*. Also, 53.3 and 66.7% of the mutants included higher activities against *Klebsiella pneumoniae* and *Bacillus subtilis*, respectively, compared to those of the parental strains. Mutant BM4 represented the highest antimicrobial activities against all indicator microorganisms ranged from 41.8 (*S. aureus*) to 131.8% (*Listeria monocytogenes*).

Mutagenesis of LAB strains is widely used for the improvement of LA production using various mutagens [23,26,27]. Bacteriocins production from *L. plantarum* was enhanced utilizing UV, followed by NTG and an improvements of 290 [46] and 266% [47] were achieved. Deletion of the gene encoding Abrb protein resulted in an 84-fold increase in subtilisin by *Bacillus subtilis* when cultured under oxygen-limiting conditions compared to under aerobic conditions [48].

3.5. Intergeneric protoplast fusion

The best hyper-producing mutants LM 6, LM 13, BM 4, and BM 12 were selected for protoplast fusion. First, the mutants were assessed for their antibiotic susceptibility responses and data indicated that, LM 6 and LM 13 were resistant to kanamycin, streptomycin and tobramycin (Table 8). Additionally, LM 13 was resistant to lincomycin. Mutant BM 4 was resistant to kanamycin, rifampicin, streptomycin and tobramycin. Mutant BM 12 was resistant to the same antibiotics except for rifampicin. Based on the antibiotic response patterns, one cross between LM 13 and BM 4 was suggested to carry out the intergeneric protoplast fusion. In further enhancing

antimicrobial activities, two parental strains of: *L. lactis* subsp. *lactis* LM 13 and *B. longum* BM 4 were used and fusants resisted lincomycin and rifampicin were selected. The fusants were assessed for their antimicrobial activity (Table 9).

Table 8. Antibiotic susceptibility of the selected bacteriocins hyper-producing mutants

Mutant	Antibiotic disc							
	*AMP +10	C 30	ERY 15	K 30	L 2	RI 30	S 10	TOB 30
LM6	16	**21	20	R	8	12	R	R
LM13	15	23	21	R	R	19	R	R
BM4	20	25	23	R	12	R	R	R
BM12	18	25	20	R	12	20	R	R

*AMP, ampicillin; C, chloramphenicol; ERY, erythromycin; K, kanamycin; L, lincomycin; RI, rifampicin; S, streptomycin; TOB, tobramycin. + Concentration ($\mu\text{g}/\text{disc}$). R= resisted (no clear zone).

** Means of diameter of inhibition zones.

Totally, 12 fusants were obtained, however, only F1 fusant exhibited higher ($p<0.05$) antagonistic effects against all indicator microorganisms, compared to those of the parental strains LM 13 and BM 4 did. The improvement range was from 13.7 (*Listeria monocytogenes*) to 44.2 % (*Salmonella typhimurium*). After a successful mutation followed by protoplast fusion, increased range of 58.1 (*Listeria monocytogenes*) to 345.7% (*Bacillus subtilis*) was achieved compared to the parental strain of *L. lactis* subsp. *lactis*. Increased range of 51.5 (*Staphylococcus aureus*) to 168.5% (*E. coli*) was also obtained compared to *B. longum* parental strain.

Table 9. Antagonistic activity of the parental strains (LM 13 and BM 4) and their fusants.

Fusants	Indicator microorganisms						
	<i>Staphylococcus aureus</i>	<i>Salmonella typhimurium</i>	<i>Bacillus cereus</i>	<i>Bacillus subtilis</i>	<i>Escherichia coli</i>	<i>Klebsiella pneumoniae</i>	<i>Listeria monocytogenes</i>
	Inhibition zone (mm \pm SD)						
LM13	*12.6 ^c _d \pm 0.05	12.0 ^c _d \pm 0.00	16.0 ^a _b \pm 0.05	14.6 ^{ab} _c \pm 0.05	18.0 ^b _a \pm 0.00	10.6 ^b _e \pm 0.05	14.6 ^{ab} _c \pm 0.05
BM4	14.6 ^b _{cd} \pm 0.81	16.3 ^b _a \pm 0.00	14.6 ^b _{bc} \pm 0.05	13.6 ^b _d \pm 0.05	16.3 ^c _a \pm 0.00	10.6 ^b _e \pm 0.05	15.3 ^{ab} _b \pm 0.00
F1	15.6 ^a _c \pm 0.05	17.3 ^b _b \pm 0.05	17.3 ^a _b \pm 0.05	15.6 ^a _c \pm 0.05	19.6 ^a _a \pm 0.05	12.6 ^a _d \pm 0.05	16.6 ^b _{bc} \pm 0.09
F2	5.3 ^{fg} _d \pm 0.05	8.6 ^d _{abc} \pm 0.05	5.6 ^e _d \pm 0.05	8.3 ^e _{bc} \pm 0.05	7.6 ^{gh} _c \pm 0.05	9.3 ^{cd} _{ab} \pm 0.05	9.6 ^{ef} _a \pm 0.05
F3	7.6 ^e _c \pm 0.05	3.6 ^h _d \pm 0.05	1.1 ^c _a \pm 0.09	11.6 ^c _a \pm 0.05	9.3 ^f _b \pm 0.05	10.0 ^{bc} _b \pm 0.00	12.3 ^{cd} _a \pm 0.05
F4	4.3 ^g _d \pm 0.05	8.6 ^d _b \pm 0.05	5.0 ^d _d \pm 0.08	5.0 ^f _d \pm 0.00	8.0 ^g _{bc} \pm 0.05	7.3 ^e _c \pm 0.05	13.6 ^{bc} _a \pm 0.05
F5	13.3 ^{bc} _a \pm 0.05	12.6 ^c _a \pm 0.05	12.3 ^c _{ab} \pm 0.05	8.6 ^{de} _d \pm 0.05	11.0 ^e _c \pm 0.08	8.6 ^d _d \pm 0.05	11.3 ^{de} _{bc} \pm 0.05
F6	10.6 ^d _c \pm 0.05	12.0 ^b _b \pm 0.08	12.3 ^c _b \pm 0.05	9.6 ^d _c \pm 0.05	12.6 ^d _{ab} \pm 0.05	9.6 ^{bcd} _c \pm 0.05	13.6 ^{bc} _a \pm 0.05
F7	6.3 ^f _b \pm 0.05	5.6 ^f _b \pm 0.05	2.6 ^f _c \pm 0.05	3.0 ^h _c \pm 0.08	5.6 ^{ij} _b \pm 0.05	3.6 ^{fg} _c \pm 0.05	12.3 ^{cd} _a \pm 0.05
F8	5.3 ^{fg} _b \pm 0.05	4.6 ^g _b \pm 0.05	2.6 ^f _c \pm 0.05	3.6 ^{gh} _{bc} \pm 0.07	5.3 ⁱ _b \pm 0.05	4.6 ^f _b \pm 0.05	8.0 ^{fg} _a \pm 0.22
F9	9.6 ^d _a \pm 0.05	7.3 ^e _b \pm 0.05	5.6 ^g _{bc} \pm 0.05	4.3 ^{fg} _{cd} \pm 0.05	3.3 ^k _d \pm 0.12	3.3 ^g _d \pm 0.05	7.0 ^{gh} _b \pm 0.22
F10	5.6 ^f _{cd} \pm 0.05	7.3 ^e _b \pm 0.00	9.6 ^d _a \pm 0.05	5.3 ^f _d \pm 0.05	8.6 ^{fg} _a \pm 0.05	6.6 ^{bc} _a \pm 0.05	8.6 ^{fg} _a \pm 0.02
F11	9.6 ^d _a \pm 0.05	9.0 ^d _a \pm 0.05	6.0 ^g _{bc} \pm 0.08	3.0 ^h _d \pm 0.08	6.6 ^{hi} _b \pm 0.05	4.6 ^f _{cd} \pm 0.12	6.6 ^{gh} _b \pm 0.12
F12	10.6 ^d _a \pm 0.05	4.6 ^g _{bc} \pm 0.05	5.6 ^e _b \pm 0.05	5.0 ^f _b \pm 0.08	5.3 ^j _b \pm 0.05	3.6 ^{fg} _c \pm 0.05	5.0 ^h _b \pm 0.08

*Means followed by different superscripts (within columns) and different subscripts (within rows) are significantly different ($p<0.05$).

Zhang et al. [49] improved nisin production of *L. lactis* subsp. *lactis* from 500 to 14000 IU ml⁻¹ using UV-irradiation followed by four rounds of protoplast fusion. Nitrosoguanidine followed by protoplast fusion was applied by Dahikar and Bhutada [30] to enhance LA production from *L. rhamnosus* with only a slight increase (83.6%).

4. Conclusion

In conclusion, EMS mutagenesis followed by intergeneric protoplast fusion successfully resulted in obtaining four hyper-bacteriocins producing mutants as well as one fusant. Such mutants and fusant can include a great economic values.

5. Conflict of Interest

The authors report no conflicts of interest.

References

- Liao SF, Nyachoti CM. Using probiotics to improve swine gut health and nutrient utilization. *Anim Nutr.* 2017; 3:331-343. doi: 10.1016/j.aninu.2017.06.007.
- Abbaslasi S, Tan JS, Ibrahim TAT, Bashokouh F, Ramakrishnan NR, Mustafa S, Ariff AB. Fermentation factors influencing the production of bacteriocins by lactic acid bacteria. A review. *RSC Adv.* 2017; 7: 29395-29420. doi: 10.1039/c6ra24579j.
- Zarrabi A, Alipoor MA, Khorasani S, Mohammadabadi M, Jamshidi A, Torkaman S, Taghavi E, Mozafari MR, Rasti B. Nanoliposomes and tocosomes as multifunctional nanocarriers for the encapsulation of nutraceutical and dietary molecules. *Molecules* 2020; 25 (3): 638-660 doi: 10.3390/molecules25030638.
- Cotter PD, Ross RP, Hill C. Bacteriocins a viable alternative to antibiotics. *Nat Rev Microbiol.* 2012; 11:95-105. doi:10.1038/nrmicro2937.
- de Vos WM, Kuipers OP, Van der Meer JR, Siezen RJ. Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by Gram-positive bacteria. *Mol. Microbiol.* 1995; 17: 427-437. doi: 10.1111/j.1365-2958.1995.mmi_17030427.x.
- Ramu R, Shirahatti PS, Devi AT, Prasad A. Bacteriocins and their applications in food preservation. *Food Sci Nutr.* 2015; 20:1-42. doi: 10.1080/10408398.2015.1020918.
- Abdelrazak A, Elaasser MM, Elshal M, Haraun SA. Bacteriocin production by newly isolated *Lactobacillus* strain. *J Pharm Biotechnol Sci.* 2016; 11:39-49. doi: 10.9790/30-1103013949.
- Sieiro PA, Lopez MM, Mu D, Kuiperes OP. Bacteriocins of lactic acid bacteria: extending the family. *Appl Microbiol Biotechnol.* 2016; 100:2939-2951. doi:10.1007/s00253-016-7333-9.
- Ni Z, Zhang X, Liu F, Wang M, Hao R., Ling P, Zhu X. Effect of Co-overexpression of nisin key genes on nisin production improvement in *Lactococcus lactis* LS01. *Probiotics Antimicro Prot.* 2017; 9:204-212. doi: 10.1007/s12602-017-9268-8.
- Al-sheddy I, Al-Dagal M, Bazaraa WA. Microbial and sensory quality of fresh camel meat treated with organic acid salts and/or bifidobacteria. *J Food Sci.*1999; 64: 336-339. doi: 10.1111/j.1365-2621.1999.tb15895.x
- da Costa RJ, Voloski FLS, Mondadori RG, Duval EH, Fiorentini AM. Preservation of meat products with bacteriocins produced by lactic acid bacteria isolated from meat. *J Food Qual.* 2019; 11:1-12. doi:10.1155/2019/4726510.
- Silva CG, Sovia PMS, Ribeiro SC. Application of bacteriocins and protective cultures in dairy food preservation. *Front Microbiol.* 2018; 9:1-15. doi: 10.3389/fmicb.2018.00594
- Acuna L, Carbalan N, Baluja MQ, Velazquez JB, Bellomio A. Expression of the hybrid bacteriocin Ent 35-Mccv in *Lactococcus lactis* and its use for controlling *Listeria monocytogenes* and *Escherichia coli* in milk. *Int Dairy J.* 2020; 104:125-131. doi: 10.1016/j.idairyj.2020.104650
- Al-Dagal MM, Bazaraa WA. Extension of shelf life of whole and peeled shrimp with organic acids salts and bifidobacteria. *J Food Prot.* 1999; 62: 51-56. doi:10.4315/0362-028x-62.1.51.
- Bazaraa WA, Abdel Aziz ME, Goda HA, Addel Kader SN. Biopreservation of the fresh Egyptian Nile perch fillets using combination of bacteriocins, sodium acetate and EDTA. *Biosci Res.* 2019; 16:1060-1075.
- Linares-Morales JR, Gutierrez-Mendez N, Rivera-Chavira BE, Perez-Vega SB, Nevarez-Moorillon GV. Biocontrol processes in fruits and fresh produce, the use of lactic acid bacteria as a sustainable option. *Front Sustain Food Syst.* 2018; 50: 1-13. doi: 10.3389/fsufs.2018.00050
- Aloui H, Khwaldia K. Natural antimicrobial edible coatings for microbial safety and food quality enhancement. *Comp Rev Sci Food Safety.* 2016; 15: 1080-1103. doi:10.1111/1541-4337.12226.
- Hammami R, Fliss T, Corsetti A. Application of protective cultures and bacteriocins for food biopreservation. *Front Microbiol.* 2019; 10:1-2. doi: 10.3389/fmicb.2019.01561
- Leja K, Myszkak AK, Czaczek K. Genome shuffling: a method to improve biotechnological processes. *J Biotechnol.* 2011; 92:345-351. doi: 10.5114/bta.2011.46551
- Khattab AA. Molecular and biochemical studies of genetically constructed lactic acid bacteria, Ph.D. Thesis, Tanta University, Egypt. 2002.
- Khattab AA, Ibrahim MIM, EL-Kady AA. Ochratoxin A biosorption on to genetically improved of *Lactobacillus delbrueckii* mutants. *Int Food Res J.* 2018; 25(2): 515-522.
- Biot-Pelletier D, Martin VJ. Evolutionary engineering by genome shuffling. *Appl Microbiol Biotechnol.* 2014; 98:3877-3887. doi: 10.1007/s00253-014-5616-8.
- John RP, Nampoothiri KM. Strain improvement of *Lactobacillus delbrueckii* using nitrous acid mutation for L-lactic acid production. *World J Microbiol Biotechnol.* 2008; 24: 3105-3109. doi: 10.1007/s11274-008-9826-z

24. Almalk AM. Production of medically important lactic acid by *Lactobacillus pentosus*: A biological conversion method. *Indian J Sci Technol*. 2016; 9: 2-7. doi: 10.17485/ijst/2016/v9i4/84143.
25. Sharma N, Prakash A. Effect of UV and microwave irradiations on *Lactobacillus fermentum*. *IIS Univ J Sci Technol*. 2015; 4: 11-18.
26. Hu W, Chen J, Wu Q, Li W, Liu J, Lu D, Wang S. The mutagenesis of *Lactobacillus thermophilus* for enhanced L- (+)-lactic acid accumulation induced by heavy ion irradiation. *Braz Arch Biol Technol*. 2017; 60: 1-11. doi: 10.1590/1678-4324-2016160337.
27. Abdallah NA, Hussein HA, Khalil OA, Aal SA, El desokey RA. Enhancement of lactic acid bacteria by Gamma radiation to inhibit antibiotic resistance of some *Salmonella* spp. *Arab J Nucl Sci Appl*. 2018; 51: 100-107. doi:10.21608/AJNSA.2018.12403.
28. Heidarpour F, Mohammadabadi MR, Zaidul ISM, Maherani B, Saari N, Hamid AA, Abas F, Manap MYA, Mozafari MR. Use of prebiotics in oral delivery of bioactive compounds: A nanotechnology perspective. *Pharmazie* 2011; 66 (5): 319-324. doi: 10.1691/ph.2011.0279
29. Wang Y, Li Y, Pei X, Yu L, Feng Y. Genome-shuffling improved acid tolerance and L-lactic acid volumetric productivity in *Lactobacillus rhamnosus*. *J Biotechnol*. 2007; 129:510-515. doi: 10.1016/j.jbiotec.2007.01.011.
30. Dahikar SB, Bhutada SA. Genome shuffling of *Lactobacillus rhamnosus* for improved production of lactic acid. *Int Biol Res*. 2017; 2:142-146.
31. Thomas BT, Agu GC, Makanjuola SO, Popoola OD. Genome shuffling of *Lactobacillus fermentum* for improved production of lactic acid. *American J Res Comm*. 2014; 2: 245-250.
32. Singhvi M, Gurjar G, Gupta V, Gokhale D. Biocatalyst development for lactic acid production at acidic pH using intergeneric protoplast fusion. *RSC Adv*. 2015; 5: 2024-2031. doi: 10.1039/c4ra11104d
33. Wang H, Sun Y, Chen C, Sun Z, Zhou YC, Shen F, Zhang H, Dai Y. Genome shuffling of *Lactobacillus plantarum* for improving antifungal activity. *Food Control*. 2013; 32: 341-347. doi: 10.1016/j.foodcont.2012.12.020
34. Kirby-Bauer A. Susceptibility test with single, high-concentration antimicrobial discs. *Antimicrob Agents Chemother*. 1979; 3:324-418.
35. Lee-Wickner LJ, Chassy B. Production and regeneration of *Lactobacillus casei* protoplasts. *Appl Environ Microbiol*. 1984; 48: 994-1000. doi: 10.1128/AEM.48.5.994-1000.1984
36. Efthymiou C, Hansen PA. An antigenic analysis of *Lactobacillus acidophilus*. *J Infect Dis*. 1962; 110: 258-267. doi:10.1093/infdis/110.3.258.
37. Chassy MB. Prospects for the genetic manipulation of *Lactobacilli*. *FEMS Microbiol Lett*. 1987; 46: 297-312. doi:10.1111/j.1574-6968.1987.tb02467.x.
38. Snedecor GW, Cochran WG. *Statistical Methods*. 7th edition. Ames (IA): Iowa State University Press. 1980. pp: 237-252
39. Nomoto K. Prevention of infections by probiotics. *J Biosci Bioeng*. 2005; 100: 583-592. doi: 10.1263/jbb.100.583.
40. Sarika AR, Lipton AP, Aishwarya MS, Dhivya RS. Efficacy of bacteriocin of *Enterococcus faecalis* CD1 as a biopreservative for high value marine fish reef cod (*Epinephelus diacanthus*) under different storage conditions. *J Microbiol Biotechnol Res*. 2011; 1:18-24.
41. Raichurkar SJ, Athawale GH. Biopreservative: Bacteriocin its classification and applications in food. *Food Sci Res J*. 2015; 6: 363-374. doi:10.15740/HAS/FSRJ/6.2/363-374
42. Rabie MA, Moustafa MG, Abdel-Wahed EM, Al-Harby BK, El-Zahar K. Bacteriocin-like substances produced by specific strains of lactic acid bacteria isolated from milk products. *J Microbiol*. 2018; 13: 70-83. doi: 10.3923/jm.2018.70.83
43. Joshi VK, Sharma S, Rana NS. Production, purification, stability and efficacy of bacteriocin from isolates of natural lactic acid fermentation of vegetables. *Food Technol Biotechnol*. 2006; 44: 435-439.
44. Khan A, Vu KD, Riedl B, Lacroix M. Optimization of the antimicrobial activity of nisin, Na-EDTA and pH against Gram negative and Gram-positive bacteria. *LWT Food Sci Technol*. 2015; 61: 124-129. doi: 10.1016/j.lwt.2014.11.035
45. Adesina IA, Enerijiofi KE. Effect of pH and heat treatment on bacteriocin activity of *Pediococcus pentosaceus* IO1, *Tetragenococcus halophilus* PO9 and *Lactobacillus cellobiosus* BE1. *Sau Sci Tech J*. 2016; 1:113-118.
46. Margino S, Winarti S, Indrati R, Rahayu SE. Mutation technique for increasing the production of antibacterial *Lactobacillus plantarum* TGR-2. *Indonesian Food Nutr Progr*. 1998; 5:73-78. doi: 10.22146/jifnp.71
47. Hussein MA. Strain improvement of *Lactobacillus plantarum* for production of bacteriocin and their purification and characterization. *Eur J Biotechnol Biosci*. 2017; 5: 59-62.
48. Stein T. Oxygen-limiting growth conditions and deletion of the transition state regulator protein Abrb in *Bacillus subtilis* 6633 result in an increase in subtilisin production and a decrease in subtilisin production. *Probiotics Antimicrob Proteins* 2020; 12(2): 725-731. doi: 10.1007/s12602-019-09547-4.
49. Zhang YF, Liu SY, Du YH, Feng WJ, Liu JH, Qiao JJ. Genome shuffling of *Lactococcus lactis* subspecies *lactis* YF11 for improving nisin Z production and comparative analysis. *J Dairy Sci*. 2014; 97: 2528-2541. doi: 10.3168/jds.2013-7238

جهش‌زایی و ادغام پیش‌یاخته به‌منظور افزایش تولید باکتریوسین‌ها وائل أحمد بازرع^{۱*}، عبدالناصر عبدالحافظ خطاب^۲، ایمان محمد ابراهیم^۳

۱- گروه علوم غذایی، دانشکده کشاورزی، دانشگاه کایرو، جیزه، ۱۲۶۱۳، مصر.

۲- گروه ژنتیک و سیتولوژی، بخش مهندسی ژنتیک و زیست فناوری، مرکز ملی تحقیقات، جیزه، ۱۲۶۲۲، مصر.

۳- مرجع ملی ایمنی مواد غذایی، کایرو، ۱۱۵۶۲، مصر.

چکیده

سابقه و هدف: جهش‌زایی القایی به‌طور گسترده برای تولید جهش‌های جدید با بازدهی بهبود یافته مورد استفاده قرار می‌گیرد. به‌منظور بهبود گونه‌های باکتری‌های لاکتیک اسید دارای فعالیت بالای ضد میکروبی، جهش‌زایی القایی با اتیل متان سولفونات به‌دنبال ادغام اینترژنریک پیش‌یاخته انجام شد.

مواد و روش‌ها: فعالیت‌های آنتاگونیستی هفت گونه باکتری‌های لاکتیک اسید در برابر هفت میکروارگانسیم شناساگر به‌روش انتشار چاهک بررسی شد. دو گونه با بیشترین اثر با اتیل متان به‌دنبال ادغام اینترژنریک پیش-یاخته، جهش‌زایی شدند. انتخاب جهش یافته‌ها و ادغام کننده‌ها بر اساس پاسخ به آنتی‌بیوتیک‌های گوناگون بوده است.

یافته‌ها و نتیجه‌گیری: لاکتوباسیلوس لاکتیس زیرگونه لاکتیس و بیفیدوباکتریوم لانگام بیشترین فعالیت ضد میکروبی در برابر اغلب میکروارگانسیم‌های شناساگر را داشتند. چنین فعالیتی در pH برابر ۲ حاصل شد و با افزایش pH کاهش چشمگیری داشت. با جهش‌های القایی اتیل متان سولفونات سی جهش‌یافته به‌دست آمد، که سه تا از آنها فعالیت بیشتری در مقایسه با انواع گونه‌های والد (دو تا برای هر والد) داشتند. جهت افزایش این فعالیت، ادغام اینترژنریک پیش‌یاخته‌های LM 13 (حاصل لاکتوباسیلوس لاکتیس زیرگونه لاکتیس) و BM 4 (حاصل بیفیدوباکتریوم لانگام) انجام شد و ۱۲ ادغام یافته به‌دست آمد. جالب اینکه، در یک ادغام یافته (F1) فعالیت ضد میکروبی در مقایسه با گونه‌های والدش افزایش داشت. افزایش ۵۸/۱ تا ۳۴۵/۷ درصدی در مقایسه با گونه والد لاکتوباسیلوس لاکتیس زیرگونه لاکتیس و ۵۱/۵ تا ۱۶۸/۵ درصدی برای دومین گونه والد مشاهده شد. جهش‌یافته‌های LM 6، LM 13، BM 4، و BM 12 و ادغام یافته F1 می‌توانند در نگهداری فرآورده‌های غذایی مورد استفاده قرار گیرند.

تعارض منافع: نویسندگان اعلام می‌کنند که هیچ نوع تعارض منافی مرتبط با انتشار این مقاله ندارند.

تاریخچه مقاله

دریافت ۹ اکتبر ۲۰۲۰

داوری ۲ دسامبر ۲۰۲۰

پذیرش ۱۲ ژانویه ۲۰۲۱

واژگان کلیدی

- باکتریوسین‌ها
- بیفیدوباکتریوم لانگام
- اتیل متان سولفونات
- ادغام پیش‌یاخته اینترژنریک
- لاکتوباسیلوس لاکتیس زیرگونه لاکتیس

*نویسنده مسئول

وائل أحمد بازرع

گروه علوم غذایی، دانشکده کشاورزی، دانشگاه کایرو، جیزه، ۱۲۶۱۳، مصر.

تلفن: ۰۰۲۰۱۰۰۴۱۵۴۹۴۹

پست الکترونیک:

waelbazaraa@hotmail.com